ASH 2013: Emergent's otlertuzumab maintains ORR lead in Phase II

 
• By Mandy Jackson
  
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas